Also known as 1-methyl-d-tryptophan (D-1-MT), indoximod, in contrast to direct IDO1 enzymatic inhibitors, acts as an IDO1-pathway modulator.143 Similar to Bristol-Myers Squib’s BMS-986205, NewLink Genetics did not commence its Phase 3 clinical trial of indoximod combined with pembrolizumab or nivolumab for patients with advanced melanoma. The gene discussed is IDO1; the disease is melanoma.